Loading organizations...
GxPartners operates as a venture capital firm, focusing its investments on early-stage companies primarily within the healthcare, biotech, and regulated manufacturing sectors. The firm provides crucial capital, strategic guidance, and hands-on support to help engineering-focused startups effectively navigate the often-complex quality, regulatory, and engineering challenges inherent to these highly specialized industries. Their approach emphasizes de-risking early-stage ventures by embedding expertise in areas critical for FDA compliance, product development, and market entry. Randall Gasa serves as a Managing Partner, playing a key role in shaping investment strategies and guiding portfolio companies through their critical growth phases. While specific financial metrics, such as assets under management or detailed portfolio company information, are not publicly available, GxPartners' operational model underscores a deep, hands-on engagement with its investments to foster innovation.
GxPartners has 4 tracked investments across 4 companies. The latest tracked deal is $1.4M Pre-Series A in REVORN in June 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 5, 2024 | REVORN | $1.4M Pre-Series A | — | Archetype Ventures, FFG Venture Business Partners, General Asahi, Monozukuri Ventures |
| Apr 8, 2024 | Payn | $920K Pre-Series A | — | Gazelle Capital, SMBC Venture Capital, Yamaguchi Capital, Yoshix Capital |
| Feb 28, 2024 | Orosy | $2.0M Series A | Hiroshi OKA | Masaki Yamamoto, Yusuke Sato, 渡邉 祐子 |
| Jun 28, 2023 | Mogumo | $1.3M Pre-Series A | Japan Venture Capital | Omoya, Orso, Zero TEN |